Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Q32 Bio Inc (QTTB)

Q32 Bio Inc (QTTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference PR Newswire - Wed Apr 8, 5:59AM CDT

WALTHAM, Mass. , April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 5.47 (-7.29%)
Q32 Bio: Q4 Earnings Snapshot AP - Tue Mar 10, 6:14AM CDT

Q32 Bio: Q4 Earnings Snapshot

QTTB : 5.47 (-7.29%)
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update PR Newswire - Tue Mar 10, 5:59AM CDT

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 --

QTTB : 5.47 (-7.29%)
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR Newswire - Wed Feb 18, 5:59AM CST

WALTHAM, Mass. , Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 5.47 (-7.29%)
Q32 Bio Announces $10.5 Million Registered Direct Offering PR Newswire - Tue Feb 17, 5:59AM CST

WALTHAM, Mass. , Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 5.47 (-7.29%)
A glass jar full of pennies_ Image by John Brueske via Shutterstock_
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? Barchart - Tue Dec 2, 2025

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.

QTTB : 5.47 (-7.29%)
AKBA : 1.4350 (+3.99%)
Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire - Mon Dec 1, 2025

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

AKBA : 1.4350 (+3.99%)
QTTB : 5.47 (-7.29%)
Akebia Announces Establishment of Rare Kidney Disease Pipeline GlobeNewswire - Mon Dec 1, 2025

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease...

AKBA : 1.4350 (+3.99%)
QTTB : 5.47 (-7.29%)
Q32 Bio: Q3 Earnings Snapshot AP - Thu Nov 13, 2025

Q32 Bio: Q3 Earnings Snapshot

QTTB : 5.47 (-7.29%)
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire - Thu Nov 13, 2025

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 --

QTTB : 5.47 (-7.29%)

Barchart Exclusives

Tesla Must Reckon with a ‘Material Collapse’ in Performance Ahead of Earnings. What Will the Outcome Be for TSLA Stock? Barchart - 49 seconds ago
JPMorgan has reiterated its "Underweight" rating on the EV heavyweight. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.